Russell Investments Group Ltd. Cuts Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Russell Investments Group Ltd. reduced its position in Supernus Pharmaceuticals by 22.2% in the first quarter, now holding 75,030 shares valued at approximately $2.5 million.
• Insider trading activity included significant sales by Director Frederick M. Hudson and CEO Jack A. Khattar, with Khattar selling 140,000 shares for nearly $5.9 million.
• Several analysts have provided positive outlooks on Supernus Pharmaceuticals, with Zacks upgrading the stock from a "strong sell" to a "hold" and Cantor Fitzgerald increasing the price target to $46.00.

Russell Investments Group Ltd. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 22.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,030 shares of the specialty pharmaceutical company's stock after selling 21,365 shares during the quarter. Russell Investments Group Ltd. owned 0.13% of Supernus Pharmaceuticals worth $2,457,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of SUPN. Raiffeisen Bank International AG purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $25,000. Financial Management Professionals Inc. purchased a new position in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $30,000. Versant Capital Management Inc increased its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after purchasing an additional 1,109 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $42,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Supernus Pharmaceuticals by 39.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,163 shares of the specialty pharmaceutical company's stock worth $114,000 after purchasing an additional 889 shares in the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 1,000 shares of the business's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $45.00, for a total value of $45,000.00. Following the completion of the sale, the chief executive officer directly owned 1,071,459 shares in the company, valued at approximately $48,215,655. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares of the company's stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,606 shares of company stock valued at $7,617,005 in the last quarter. Insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded down $0.25 during trading on Friday, reaching $45.12. The company had a trading volume of 481,773 shares, compared to its average volume of 993,234. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $45.60. The stock's 50 day moving average price is $36.63 and its two-hundred day moving average price is $33.87. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of 39.23 and a beta of 0.79.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SUPN shares. Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Piper Sandler upped their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.